#1 Clinical Trials Search in Europe

Agrostis Stolonifera Pollen

This article discusses clinical trials investigating the use of Agrostis Stolonifera Pollen, a component of a grass pollen mixture, in the treatment of moderate to severe allergic rhinitis or rhinoconjunctivitis caused by house dust mite allergy. The trials aim to assess the efficacy and safety of subcutaneous immunotherapy using this pollen extract as part of a comprehensive allergen mixture.

Table of Contents

What is Agrostis Stolonifera Pollen?

Agrostis Stolonifera Pollen, also known as creeping bentgrass pollen, is a type of grass pollen that is commonly used in allergy testing and treatment[1]. It is one of several grass pollens included in a mixture used for diagnosing and treating grass pollen allergies.

Medical Use

Agrostis Stolonifera Pollen is primarily used in the diagnosis and treatment of grass pollen allergies. It is a component of a pollen mixture used in skin prick tests and immunotherapy treatments[1]. These tests and treatments are typically used for patients with moderate to severe allergic rhinitis or rhinoconjunctivitis (hay fever) caused by grass pollen allergies.

How It Works

When used in a skin prick test, a small amount of the Agrostis Stolonifera Pollen solution is placed on the skin, and the skin is then pricked. If a person is allergic to this pollen, a small, itchy bump will appear at the site of the prick. This helps doctors diagnose specific grass pollen allergies[1].

In immunotherapy treatments, small amounts of the allergen (including Agrostis Stolonifera Pollen) are introduced to the patient’s body over time. This helps the immune system become less sensitive to the allergen, potentially reducing allergy symptoms[1].

Administration

Agrostis Stolonifera Pollen is typically administered as part of a mixture of grass pollens in a solution for skin prick tests. The solution is applied to the skin in small drops, usually on the forearm or back[1]. For immunotherapy treatments, it may be given as subcutaneous (under the skin) injections.

Potential Benefits

The use of Agrostis Stolonifera Pollen in allergy testing and treatment can potentially lead to:

  • Accurate diagnosis of grass pollen allergies
  • Reduced allergy symptoms through immunotherapy
  • Improved quality of life for individuals with grass pollen allergies
  • Better management of allergic rhinitis or rhinoconjunctivitis

Important Considerations

While Agrostis Stolonifera Pollen can be beneficial in allergy diagnosis and treatment, it’s important to note:

  • Skin prick tests and immunotherapy should only be performed by trained healthcare professionals.
  • Allergic reactions, including severe ones, are possible during testing or treatment.
  • Agrostis Stolonifera Pollen is often used as part of a mixture with other grass pollens, not as a standalone treatment.
  • The effectiveness of immunotherapy can vary from person to person.
  • Regular follow-ups with an allergist are important to monitor progress and adjust treatment as needed.

Always consult with a healthcare professional for personalized advice and treatment options for grass pollen allergies.

Aspect Details
Study Type Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study
Treatment PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy
Target Condition Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) Allergy
Primary Objective Assess clinical efficacy measured by Total Combined Rhinitis Score (TCRS)
Key Inclusion Criteria Adults 18-65 years, HDM allergic rhinitis history, positive skin prick test, specific IgE levels, and symptom severity
Key Exclusion Criteria Severe immune disorders, active malignancies, moderate to severe asthma, history of anaphylaxis
Treatment Duration Approximately 52 weeks
Primary Endpoint Average daily TCRS during the last 8 weeks of treatment

FAQ

  • What is the main purpose of the clinical trial involving Agrostis Stolonifera Pollen? The main purpose is to assess the effectiveness of a subcutaneous immunotherapy treatment containing Agrostis Stolonifera Pollen (as part of a grass pollen mixture) for adults with moderate to severe allergic rhinitis or rhinoconjunctivitis caused by house dust mite allergy.
  • Who can participate in this clinical trial? Participants must be adults aged 18-65 with a history of moderate to severe house dust mite allergic rhinitis for at least one year, have positive skin prick tests to house dust mites, and meet specific criteria for symptom severity and lung function.
  • How is the effectiveness of the treatment measured? The main measure of effectiveness is the difference in the average Total Combined Rhinitis Score (TCRS) during the last 8 weeks of one year of treatment between the active treatment group and the placebo group.
  • What are some of the exclusion criteria for this trial? Exclusion criteria include severe immune disorders, active malignancies, moderate to severe asthma, history of anaphylaxis, and previous long-term allergen immunotherapy treatments within the last 5 years.
  • How long does the clinical trial last? The total treatment period should be within 52 weeks, including an initial up-dosing phase followed by maintenance injections over the course of about one year.

Ongoing Clinical Trials on Agrostis Stolonifera Pollen

  • Study on the Effectiveness of PURETHAL Mites for Adults with Moderate to Severe Allergic Rhinitis or Rhinoconjunctivitis Due to House Dust Mite Allergy

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Bulgaria Germany Latvia Lithuania Poland

Glossary

  • Allergic Rhinitis: An allergic reaction affecting the nasal passages, causing symptoms such as sneezing, runny nose, and congestion in response to allergens like house dust mites or pollen.
  • Rhinoconjunctivitis: A condition where both the nasal passages and eyes are affected by an allergic reaction, causing symptoms in both areas.
  • Subcutaneous Immunotherapy (SCIT): A treatment method where small amounts of allergens are injected under the skin to help the body build tolerance to those allergens over time.
  • House Dust Mite (HDM): Tiny insects that commonly live in house dust and are a frequent cause of allergies in many people.
  • Total Combined Rhinitis Score (TCRS): A measure used to assess the severity of rhinitis symptoms, combining individual symptom scores into a total score.
  • Nasal Provocation Test (NPT): A test where allergens are applied directly to the nasal passages to observe and measure the allergic response.
  • Forced Expiratory Volume 1 (FEV1): A lung function test that measures how much air a person can exhale in one second, used to assess breathing capacity.
  • Immunoglobulin E (IgE): An antibody produced by the immune system in response to allergens, often elevated in allergic conditions.
  • Skin Prick Test (SPT): A method of testing for allergies by applying small amounts of potential allergens to the skin and observing the reaction.
  • Rhinitis Medication Score (RMS): A score that measures the amount and type of medication needed to control rhinitis symptoms.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-purethal-mites-for-adults-with-moderate-to-severe-allergic-rhinitis-or-rhinoconjunctivitis-due-to-house-dust-mite-allergy/